947 / 1631
A molecular precision approach to DLBCL?...almost
•
Don’t think of DLBCL as one disease
•
There are challenges in defining molecular sub-groups in a timely fashion and the
appropriate diagnostic platform.
•
Targeted therapies may potentially change the landscape of therapy for DLBCL...not yet.
Next year it may be different.
•
DHL is a special case..
•
Much still needs to be proved and phase III studies are needed (no matter how
difficult)…
•
We need to better refine the molecular heterogeneity and to continue to better exploit our
new knowledge of the biology. Outcomes in patients with R/R disease are unsatisfactory